This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Side effects

Authoring team

  • pain, swelling or redness at the injection site are common and may occur more frequently following subsequent doses
  • a small, painless nodule may form at the injection site; this usually disappears and is of no consequence
    • incidence of local reactions is lower with tetanus vaccines combined with acellular pertussis vaccines than with whole-cell pertussis vaccines, and similar to that after diphtheria (DT) vaccine

  • fever, convulsions, high-pitched screaming, and episodes of pallor, cyanosis and limpness occur with equal frequency after both DTaP and DT vaccines
  • confirmed anaphylaxis occurs extremely rarely
  • other allergic conditions may occur more commonly and are not contraindications to further immunisation (1)

  • Hib/Men C conjugate vaccine
    • mild side effects such as irritability, loss of appetite, pain, swelling, redness at the site of the injection and slighty raised temperature commonly occur
    • less commonly, crying, diarrhoea, vomiting, atopic dermatitis, malaise and fever over 39.5°C have been reported

Check The Green Book for uptodate details.

Check the Summary of Product Characteristics before prescribing/administering a Hib-containing vaccine.

Reference:

  1. Immunisation Against Infectious Disease - "The Green Book".Chapter 16 Haemophilis influenzae type B (Hib) (April 2019)

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.